154 related articles for article (PubMed ID: 19394693)
1. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
[TBL] [Abstract][Full Text] [Related]
2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
3. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
4. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
Abraham S; Salama M; Hancock J; Jacobsen J; Fluchel M
Pediatr Blood Cancer; 2012 Nov; 59(5):928-9. PubMed ID: 22488677
[TBL] [Abstract][Full Text] [Related]
5. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R
Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790
[No Abstract] [Full Text] [Related]
7. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome.
Mozziconacci MJ; Sainty D; Chabannon C
Am J Hematol; 2007 Jul; 82(7):688-9. PubMed ID: 17366548
[No Abstract] [Full Text] [Related]
8. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
[TBL] [Abstract][Full Text] [Related]
9. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
Baeumler J; Szuhai K; Falkenburg JH; van Schie ML; Ottmann OG; Nijmeijer BA
Cancer Genet Cytogenet; 2008 Aug; 185(1):37-42. PubMed ID: 18656692
[TBL] [Abstract][Full Text] [Related]
10. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.
Pitini V; Arrigo C; Teti D; Barresi G; Righi M; Alo G
Haematologica; 2003 May; 88(5):ECR18. PubMed ID: 12745287
[TBL] [Abstract][Full Text] [Related]
11. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome].
Nemchenko IS; Khoroshko ND; Turkina AG; Vinogradova OIu; Sokolova MA; Abakumov EM; Semenova EA; Zakharova AV; Domracheva EV
Ter Arkh; 2004; 76(7):87-90. PubMed ID: 15379136
[No Abstract] [Full Text] [Related]
12. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
Kim YK; Shin MG; Kim HR; Yang DH; Cho SH; Lee JJ; Chung IJ; Ryang DW; Kim HJ
Leuk Res; 2008 Jun; 32(6):993-5. PubMed ID: 18055011
[No Abstract] [Full Text] [Related]
13. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
[TBL] [Abstract][Full Text] [Related]
15. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
[TBL] [Abstract][Full Text] [Related]
16. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.
Salaroli A; Loglisci G; Serrao A; Alimena G; Breccia M
Ann Hematol; 2012 Nov; 91(11):1823-4. PubMed ID: 22623162
[No Abstract] [Full Text] [Related]
17. Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.
Yao J; Xu L; Aypar U; Meyerson HJ; Londono D; Gao Q; Baik J; Dietz J; Benayed R; Sigler A; Yabe M; Dogan A; Arcila ME; Roshal M; Zhang Y; Mauro MJ; Xiao W
Haematologica; 2021 Feb; 106(2):614-618. PubMed ID: 32299902
[No Abstract] [Full Text] [Related]
18. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
[No Abstract] [Full Text] [Related]
19. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia.
Kelly JC; Shahbazi N; Scheerle J; Jahn J; Suchen S; Christacos NC; Mowrey PN; Witt MH; Hostetter A; Meloni-Ehrig AM
Cancer Genet Cytogenet; 2009 Jul; 192(1):36-9. PubMed ID: 19480935
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
